ORIC Pharmaceuticals, Inc. (ORIC)

NASDAQ • Healthcare

$13.17

-$0.46 (-3.4%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$13.1

Previous Close$13.17

Day Range$12.73 - $13.49

Avg. Volume (3M)1.4M

Market Cap$1.3B

52 Week Range

$7.23$14.68

Next EarningsIn 18 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$140.3M

EPS (TTM)

-$1.35

ROA (TTM)

-34.68%

Current Ratio

13.19

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-2.2%Q3 2025-$0.47

+19.5%Q4 2025-$0.33

+11.8%Q1 2026-$0.3

-6.0%Q2 2026-$0.34

-5.7%Q3 2026-$0.38

Nov 12

in 18 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -5.7%

ORIC Pharmaceuticals’ earnings trailed consensus as EPS came in at -$0.38 versus the -$0.36 estimate (difference -$0.02), based on preliminary results for the second fiscal quarter of 2026 that were reported on August 3, 2026. The company posted a GAAP net loss of about $41.5 million, down ~14% from a net loss of roughly $36.4 million a year ago, alongside GAAP operating income of around -$45.3 million as the early-stage oncology pipeline (including ORIC-533, ORIC-944, and ORIC-114) continued to drive operating spending. Cash flow from operations was negative at about $31.6 million, and the company repurchased roughly $1.3 million of stock during the quarter. For the next period, consensus calls for EPS of -$0.40.

Next report — what to expect

ORIC Pharmaceuticals, Inc. (ORIC) reports on November 12, 2026. Consensus expects EPS of -$0.384, with recent focus likely on any updates that could shape expectations around revenue and pipeline progress. ORIC has beaten EPS in 4 of 8 most recent quarters, so traders may watch how results compare with that mixed track record.

View full earnings history

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. is a NASDAQ-listed Biotechnology company developing treatments for cancer patients in the United States. Founded in 2014 and based in South San Francisco, California, ORIC operates as an early-stage drug developer focused on precision medicines aimed at cancer resistance, and it has traded publicly since its 2020 IPO.

Name

ORIC Pharmaceuticals, Inc.

CEO

Jacob Chacko

Website

www.oricpharma.com

Industry

Healthcare

Year Founded

2014

Employees

111

Today's Snapshot

AI-generated

ORIC closed 3.4% lower at 13.17, in line with a weaker sector. ORIC Pharmaceuticals reported an 88% response rate for enozertinib, its experimental lung-cancer drug, in an early-stage study.

Trading Volume

Above 10d avg 1.4M

1.3M

vs S&P 500 Today

Underperforming Market

-2.85%

Updated: October 23, 2026 at 20:18 UTC

Technical Indicators

6 Buy2 Neutral0 Sell

ORIC sits comfortably above its short- and longer-term moving averages, signaling a constructive price structure, while MACD and short-term momentum point toward modest upside bias. Oscillators are mostly neutral and ADX indicates only modest trend strength, so the advance appears steady rather than aggressive. Volatility is moderate by ATR, and the on-balance volume measure shows buying interest despite a negative cumulative figure, suggesting accumulation on balance. Classic pivot is slightly above the market and may act as near-term resistance. Technical takeaway: Strong Buy — constructive price alignment with measured momentum and volume support.

All signals